We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01264653
Recruitment Status : Completed
First Posted : December 22, 2010
Last Update Posted : July 6, 2012
Information provided by (Responsible Party):
A-Yong Yu, Wenzhou Medical College

Brief Summary:
The purpose of this study is to study the safety and efficacy of intracameral adrenaline for pupil dilation without topical mydriatics in refractive cataract surgery.

Condition or disease Intervention/treatment
Cataract Drug: adrenalin

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Health Services Research
Official Title: Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery
Study Start Date : December 2010
Primary Completion Date : December 2011
Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: experimental group,control group
Intraocular adrenalin,topical mydriatics, experimental group: Intervention: Procedure:refractive cataract surgery with Intraocular adrenalin, control group:refractive cataract surgery with topical mydriatics
Drug: adrenalin
adrenalin 0.01%
Other Name: adrenaline hydrochloride

Primary Outcome Measures :
  1. Pupil size after intracameral adrenaline [ Time Frame: 1day ]
    We would like to evaluate Pupil size dilated with intracameral adrenaline 0.01%

Secondary Outcome Measures :
  1. endothelial cell count [ Time Frame: 1month ]
    we would like to evaluate the endothelial cell count 1 month after surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male and female
  • can read and sign informed consent form;
  • Clinical diagnosis of cataract
  • Cataract density grade II-III according to the Emery-Little system classification system

Exclusion Criteria:

  • sensitivity to adrenalin;
  • sensitivity to topical mydriatics;
  • any other ocular surgeries;
  • iris abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01264653

China, Zhejiang
Wenzhou Medical College
Wenzhou, Zhejiang, China, 325000
Sponsors and Collaborators
Wenzhou Medical University
Study Director: Ayong Yu Wenzhou Medical University

Responsible Party: A-Yong Yu, Wenzhou Medical College
ClinicalTrials.gov Identifier: NCT01264653     History of Changes
Other Study ID Numbers: Wenzhou Medical College
First Posted: December 22, 2010    Key Record Dates
Last Update Posted: July 6, 2012
Last Verified: July 2012

Keywords provided by A-Yong Yu, Wenzhou Medical College:

Additional relevant MeSH terms:
Lens Diseases
Eye Diseases
Pupil Disorders
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents